1-3 of 3
Beni B. Wolf, MD, PhD
Close
Sort by
Journal Articles

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, MD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD FRCPath, Jason Gotlib, MD, William A Robinson, MD PhD, Elizabeth Hexner, MDMS, Srdan Verstovsek, MD PhD, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Erica Evans, PhD, Mary Ellen Healy, Beni B. Wolf, MD PhD, Michael W. Deininger, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2.
https://doi.org/10.1182/blood.V130.Suppl_1.2.2
Published: 2017
Journal Articles

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Mark W. Drummond, PhD MD, Daniel J. DeAngelo, MD PhD, Michael W. Deininger, MD PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Albert Thomas Quiery, MD, Elizabeth O Hexner, MD, Hongliang Shi, MS, Terri Alvarez-Diez, PhD, Erica K. Evans, PhD, Mary Ellen Healy, MS, Beni B. Wolf, MD PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 477.
https://doi.org/10.1182/blood.V128.22.477.477
Published: 2016
Journal Articles

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Chanan-Khan, MD, Manish Patel, MD, Kevin R. Kelly, MD, Kelli L. Running, Mary Murphy, Robin Guild, Christina Carrigan, PhD, Sharron Ladd, Beni B. Wolf, MD, PhD, James J. O'Leary, MD, Sikander Ailawadhi, MD
Journal: Blood
Blood (2012) 120 (21): 728.
https://doi.org/10.1182/blood.V120.21.728.728
Published: 2012